Etranacogene dezaparvovec meets the benchmarks for success, researcher says ...

Three years after introducing Hemgenix, the first gene therapy for hemophilia B, CSL Behring has released long-term data ...

Hemophilia B, a genetic bleeding disorder caused by deficient factor IX activity, has traditionally required lifelong ...

A South Jersey college student with hemophilia B is now living a more normal life thanks to a treatment developed from ...

Hemophilia gene therapies arrived a few years ago with blockbuster expectations. But now, one therapy has been pulled from ...

For men with hemophilia B, receipt of gene therapy comprising an infusion of etranacogene dezaparvovec results in sustained ...

New gene therapies designed to cure hemophilia could cost $1.5 million or more, according to a May 7 Leerink analyst note cited by CNBC. Here are three things to know. 1. The current treatment for ...

Dec 29 (Reuters) - U.S. drugmaker Pfizer Inc (PFE.N), opens new tab said on Thursday its experimental gene therapy for the treatment of hemophilia B, a rare inherited blood disorder, met its main goal ...

The gene therapy giroctocogene fitelparvovec demonstrated superiority compared with the standard of care, routine prophylaxis, in hemophilia A treatment. Giroctocogene fitelparvovec demonstrated ...

Gene therapy for hemophilia B allowed almost three-fourths of patients to discontinue prophylactic factor IX therapy with no increase in bleeding, results of the pivotal BENEGENE-2 trial showed. The ...

Jack Grehan, who was born with hemophilia, used to inject himself every couple of days with a protein he needs for his blood to clot. But not anymore. "It's been absolutely brilliant and life-changing ...